Compare OSRH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSRH | HOTH |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 21 | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 12.8M |
| IPO Year | N/A | 2018 |
| Metric | OSRH | HOTH |
|---|---|---|
| Price | $0.54 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 15.2M | 3.0M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.49 |
| 52 Week High | $1.79 | $2.12 |
| Indicator | OSRH | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 40.19 |
| Support Level | $0.47 | $0.49 |
| Resistance Level | $0.59 | $0.80 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 28.38 | 3.25 |
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.